Recent 8-K filings for PLYX

• September 11, 2026, 7:59 PM ET other materiality 0.10 neutral item 5.07

  Polaryx shareholders re-elect Alex Yang, Mitchel Berger as Class I directors

  Alex Yang and Mitchel Berger re-elected as Class I directors at Sept 10, 2026 annual meeting.

• September 1, 2026, 4:30 PM ET leadership materiality 0.60 positive item 7.01item 8.01item 9.01

  Polaryx appoints Dr. Will Charlton as Chief Medical Officer; SOTERIA Phase 2 on track for Q4 2026

  Dr. Charlton appointed CMO effective Sept 1, 2026; brings 15+ years rare disease/pediatric drug development experience.

• July 21, 2026, 4:30 PM ET leadership materiality 0.40 neutral item 5.02

  Polaryx Therapeutics CMO Lisa Bollinger resigns effective immediately

  CMO Lisa Bollinger, MD, resigned on July 19, 2026, effective immediately.

• July 17, 2026, 8:00 AM ET other materiality 0.10 neutral item 5.08item 8.01

  Polaryx sets 2026 annual meeting for Sept 10; record date July 27

  Annual meeting will be held virtually on September 10, 2026.

• May 28, 2026, 4:31 PM ET other material materiality 0.55 neutral item 1.01item 3.02item 7.01item 9.01 ◈ Equity Issuances◈ Material Agreements

  Polaryx closes $10M PIPE at ~$4.00/share to fund Phase 2 SOTERIA basket trial

  Private placement of 2,502,696 common shares at avg $4.00/share for $10M gross proceeds to ~35 investors.

Materiality & sentiment trend

Max materiality 0.60 · Median 0.40 · Most common event other

1 positive 0 negative 4 neutral

source · PLYX on sec.gov